Advertisement

Annals of Surgical Oncology

, 10:882 | Cite as

Progression of Gene Hypermethylation in Gallstone Disease Leading to Gallbladder Cancer

  • Michael G. House
  • Ignacio I. Wistuba
  • Pedram Argani
  • MingZhou Guo
  • Richard D. Schulick
  • Ralph H. Hruban
  • James G. Herman
  • Anirban Maitra
Original Articles

Abstract

Background: Aberrant methylation of tumor-suppressor genes is associated with a loss of gene function that can afford selective growth advantages to sporadic neoplastic cells arising during gallbladder inflammation.

Methods: Fifty-four gallbladder neoplasms were selected from tumor banks in the United States and Chile. Each of the neoplasms was subjected to methylation-specific polymerase chain reaction to detect promoter methylation associated with six candidate tumor-suppressor genes (p16, APC, methylguanine methyltransferase, hMLH1, retinoic acid receptor beta-2, and p73) implicated in multiple human cancer types.

Results: Aberrant methylation of any of the six candidate tumor-suppressor genes was detected in 72% of the gallbladder neoplasms, 28% of the cases of chronic cholecystitis, and in only 1 of the 15 normal gallbladder controls. The four most commonly methylated genes in the gallbladder cancers were p16 (56%), p73 (28%), APC (27%), and hMLH1 (14%). Significant differences in gene methylation were discovered between US gallbladder cancers and those from Chile, where gallbladder cancer is one of the leading causes of cancer-related deaths. APC methylation was present in 42% of the US cases but in only 14% of the Chilean tumors (P = .028). p73 methylation was common among the Chilean cancers (40%) compared with those from the United States (13%; P = .034).

Conclusions: The acquisition of hypermethylation at multiple tumor-suppressor gene-promoter sites may contribute to tumor formation and progression within the chronically inflamed gallbladder. The apparent differences in methylation patterns among the Chilean and US gallbladder cases may indicate a unique biology associated with this cancer in different parts of the world.

Key Words

Methylation Gallbladder Cancer Tumor-suppressor genes 

REFERENCES

  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Nervi F, Duarte I, Gomez G, et al. Frequency of gallbladder cancer in Chile, a high-risk area. Int J Cancer 1988;41:657–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Khan ZR, Neugut AI, Ahsan H, Chabot JA. Risk factors for biliary tract cancers. Am J Gastroenterol 1999;94:149–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Kimura K, Ohto M, Saisho H, et al. Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 1995;76:1747–56.CrossRefPubMedGoogle Scholar
  7. 7.
    Caygill CP, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 1994;343:83–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Ajiki T, Fujimori T, Onoyama H, et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996;38:426–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ajiki T, Onoyama H, Yamamoto M, et al. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996;43:521–6.PubMedGoogle Scholar
  10. 10.
    Hanada K, Tsuchida A, Iwao T, et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999;94:1638–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Itoi T, Watanabe H, Ajioka Y, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996;46:333–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001;61:6971–6.PubMedGoogle Scholar
  13. 13.
    Kohya N, Miyazaki K, Matsukura S, et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002;9:371–9.PubMedGoogle Scholar
  14. 14.
    Quan ZW, Wu K, Wang J, et al. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001;193:380–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Roa I, Villaseca M, Araya J, et al. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997;31:226–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Suzuki T, Takano Y, Kakita A, Okudaira M. An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. Pathol Res Pract 1993;189:283–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanno S, Obara T, Fujii T, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 1998;83:267–75.CrossRefPubMedGoogle Scholar
  18. 18.
    Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999;6:237–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Shi YZ, Hui AM, Li X, et al. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000;6:4096–100.PubMedGoogle Scholar
  20. 20.
    Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Baylin S. DNA methylation and epigenetic mechanisms of carci-nogenesis. Dev Biol 2001;106:85–7; discussion 143–60.Google Scholar
  22. 22.
    Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700–4.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870–5.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ahrendt SA, Eisenberger CF, Yip L, et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 1999;84:88–93.CrossRefPubMedGoogle Scholar
  26. 26.
    Lee S, Kim WH, Jung HY, et al. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002;161:1015–22.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000;47:721–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Wong N, Li L, Tsang K, et al. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Gerdes B, Ramaswamy A, Kersting M, et al. p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. Surgery 2001;129:490–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573–7.PubMedGoogle Scholar
  33. 33.
    Azarschab P, Porschen R, Gregor M, et al. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer 2002;35:121–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Paimela H, Karppinen A, Hockerstedt K, et al. Poor prognosis of gallbladder cancer persists regardless of improved diagnostic methods. Incidence and results of surgery during 20 years in Helsinki. Ann Chir Gynaecol 1997;86:13–7.PubMedGoogle Scholar
  35. 35.
    Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67–70.PubMedGoogle Scholar
  36. 36.
    Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954–8.PubMedGoogle Scholar
  37. 37.
    Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821–6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835–9.PubMedGoogle Scholar
  41. 41.
    Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67.CrossRefPubMedGoogle Scholar
  43. 43.
    Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999;30:21–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Chang HJ, Jee CD, Kim WH. Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol 2002;26:758–66.CrossRefPubMedGoogle Scholar
  45. 45.
    Matsubara T, Sakurai Y, Sasayama Y, et al. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Cancer 1996;77(8 Suppl):1752–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Kim SW, Her KH, Jang JY, et al. K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol 2000;75:246–51.CrossRefPubMedGoogle Scholar
  47. 47.
    Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998;115:937–46.CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Michael G. House
    • 1
    • 5
  • Ignacio I. Wistuba
    • 4
  • Pedram Argani
    • 2
  • MingZhou Guo
    • 3
  • Richard D. Schulick
    • 1
  • Ralph H. Hruban
    • 3
  • James G. Herman
    • 3
  • Anirban Maitra
    • 1
  1. 1.Department of SurgeryThe Johns Hopkins Medical InstitutionsBaltimore
  2. 2.Department of PathologyThe Johns Hopkins Medical InstitutionsBaltimore
  3. 3.Department of OncologyThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore
  4. 4.Department of PathologyPontificia Universidad Catolica de ChileSantiagoChile
  5. 5.Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsTumor BiologyBaltimore

Personalised recommendations